In lung cancer, SMYD3 knockdown increases sensitivity, whereas SMYD3-overexpressing non-small cell lung cancer cells are more resistant to cisplatin-induced apoptosis because of the regulation of the Bim, BCL2 antagonist/killer (Bak), and BCL2-associated X (Bax) genes75. Here, SMYD3 is linked to lung carcinoma.